CellTrans’ Donislecel Gets US FDA Panel Nod For Small Group Of Type 1 Diabetics

 
• By Sue Sutter
  
Independence Day fireworks
Some recipients of CellTrans' donislecel are able to celebrate years of independence from insulin. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers